Fortgeschrittenes nichtkleinzelliges Lungenkarzinom
作者： W. Schütte , S. Nagel , G. Haak , M. Steinert
DOI: 10.1007/S10405-011-0501-Y
关键词:
摘要: Die Erhaltungs- und Second-line-Therapie des fortgeschrittenen Lungenkrebses hat sich in den letzten Jahren zum Standard entwickelt. Voraussetzung fur eine optimale weiterfuhrende Therapie ist genaue Analyse Tumors der First-line-Behandlung. Dazu gehoren die Feststellung EGF-Rezeptormutationsstatus Histologie sowie das Ansprechen auf Continuous- Switch-Maintenance-Therapie stehen sofortige Weiterfuhrung zur Verfugung. Bei Patientenwunsch muss Indikation gepruft werden. Substanzen kontinuierliche Behandlung sind Pemetrexed Docetaxel Tyrosinkinaseinhibitoren, Bevazicumab Cetuximab. Second-line-Behandlung sollte bei initialer Chemotherapie standardmasig mit Docetaxel, oder Erlotinib durchgefuhrt Wahl Medikamente hangt von First-line-Therapie akzeptierten Nebenwirkungen ab. Nach primarer Tyrosinkinaseinhibitor-Behandlung platinhaltige einem Taxan indiziert. genauer Abstimmung Therapielinien Patientenbedurfnisse durch Weiterentwicklung therapeutischen Moglichkeiten Patienten deutlich verbesserte Situation ergeben.
springer.com
sci-hub.se 参考文章(18)
M. Thomas, J. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, A. Zimmerman, C. M. Visseren Grul, C. Gridelli, L. G. Paz-Ares, F. De Marinis, M. Dediu, PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7510
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
T. Ciuleanu, L. Stelmakh, S. Cicenas, E. Esteban Gonzalez, 88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY Lung Cancer. ,vol. 71, ,(2011) , 10.1016/S0169-5002(11)70225-2
Han-Pin Kuo, Chih-Hsi Kuo, Shu-Min Lin, Kang-Yun Lee, Fu-Tsai Chung, Meng-Heng Hsieh, Yueh-Fu Fang, Chih-Ten Yu, Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung Cancer With Acquired Tyrosine Kinase Inhibitor Resistance Clinical Lung Cancer. ,vol. 11, pp. 51- 56 ,(2010) , 10.3816/CLC.2010.N.008
Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Aleksandra Szczésna, Erzsébet Juhász, Emilio Esteban, Olivier Molinier, Wolfram Brugger, Ivan Melezínek, Gaëlle Klingelschmitt, Barbara Klughammer, Giuseppe Giaccone, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncology. ,vol. 11, pp. 521- 529 ,(2010) , 10.1016/S1470-2045(10)70112-1
Tudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, Joo Hang Kim, Maciej Krzakowski, Eckart Laack, Yi-Long Wu, Isabel Bover, Stephen Begbie, Valentina Tzekova, Branka Cucevic, Jose Rodrigues Pereira, Sung Hyun Yang, Jayaprakash Madhavan, Katherine P Sugarman, Patrick Peterson, William J John, Kurt Krejcy, Chandra P Belani, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study The Lancet. ,vol. 374, pp. 1432- 1440 ,(2009) , 10.1016/S0140-6736(09)61497-5
Christopher G Azzoli, Sherman Baker Jr, Sarah Temin, William Pao, Timothy Aliff, Julie Brahmer, David H Johnson, Janessa L Laskin, Gregory Masters, Daniel Milton, Luke Nordquist, David G Pfister, Steven Piantadosi, Joan H Schiller, Reily Smith, Thomas J Smith, John R Strawn, David Trent, Giuseppe Giaccone, None, American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 27, pp. 6251- 6266 ,(2009) , 10.1200/JCO.2009.23.5622
Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Karin Mattson, Richard Gralla, Mark O’Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald Burkes, Susan Coughlin, Yong Kim, Jocelyne Berille, Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Journal of Clinical Oncology. ,vol. 18, pp. 2095- 2103 ,(2000) , 10.1200/JCO.2000.18.10.2095
Thomas Brodowicz, Maciej Krzakowski, Matjaz Zwitter, Valentina Tzekova, Rodryg Ramlau, Nicolae Ghilezan, Tudor Ciuleanu, Branka Cucevic, Kalman Gyurkovits, Ernst Ulsperger, Jacek Jassem, Mislav Grgic, Pinar Saip, Maria Szilasi, Christoph Wiltschke, Maria Wagnerova, Natalya Oskina, Victoria Soldatenkova, Christoph Zielinski, Miklos Wenczl, Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. ,vol. 52, pp. 155- 163 ,(2006) , 10.1016/J.LUNGCAN.2006.01.006
Loren K. Mell, James J. Dignam, Joseph K. Salama, Ezra E.W. Cohen, Blase N. Polite, Virag Dandekar, Amit D. Bhate, Mary Ellyn Witt, Daniel J. Haraf, Bharat B. Mittal, Everett E. Vokes, Ralph R. Weichselbaum, Predictors of Competing Mortality in Advanced Head and Neck Cancer Journal of Clinical Oncology. ,vol. 28, pp. 15- 20 ,(2010) , 10.1200/JCO.2008.20.9288